Erbb4 Deletion From Inhibitory Interneurons Causes Psychosis-Relevant Neuroimaging Phenotypes.
Erbb4
hippocampus
inhibitory interneurons
mice
neuroimaging
psychosis
Journal
Schizophrenia bulletin
ISSN: 1745-1701
Titre abrégé: Schizophr Bull
Pays: United States
ID NLM: 0236760
Informations de publication
Date de publication:
03 05 2023
03 05 2023
Historique:
medline:
4
5
2023
pubmed:
28
12
2022
entrez:
27
12
2022
Statut:
ppublish
Résumé
Converging lines of evidence suggest that dysfunction of cortical GABAergic inhibitory interneurons is a core feature of psychosis. This dysfunction is thought to underlie neuroimaging abnormalities commonly found in patients with psychosis, particularly in the hippocampus. These include increases in resting cerebral blood flow (CBF) and glutamatergic metabolite levels, and decreases in ligand binding to GABAA α5 receptors and to the synaptic density marker synaptic vesicle glycoprotein 2A (SV2A). However, direct links between inhibitory interneuron dysfunction and these neuroimaging readouts are yet to be established. Conditional deletion of a schizophrenia susceptibility gene, the tyrosine kinase receptor Erbb4, from cortical and hippocampal inhibitory interneurons leads to synaptic defects, and behavioral and cognitive phenotypes relevant to psychosis in mice. Here, we investigated how this inhibitory interneuron disruption affects hippocampal in vivo neuroimaging readouts. Adult Erbb4 conditional mutant mice (Lhx6-Cre;Erbb4F/F, n = 12) and their wild-type littermates (Erbb4F/F, n = 12) were scanned in a 9.4T magnetic resonance scanner to quantify CBF and glutamatergic metabolite levels (glutamine, glutamate, GABA). Subsequently, we assessed GABAA receptors and SV2A density using quantitative autoradiography. Erbb4 mutant mice showed significantly elevated ventral hippccampus CBF and glutamine levels, and decreased SV2A density across hippocampus sub-regions compared to wild-type littermates. No significant GABAA receptor density differences were identified. These findings demonstrate that specific disruption of cortical inhibitory interneurons in mice recapitulate some of the key neuroimaging findings in patients with psychosis, and link inhibitory interneuron deficits to non-invasive measures of brain function and neurochemistry that can be used across species.
Sections du résumé
BACKGROUND AND HYPOTHESIS
Converging lines of evidence suggest that dysfunction of cortical GABAergic inhibitory interneurons is a core feature of psychosis. This dysfunction is thought to underlie neuroimaging abnormalities commonly found in patients with psychosis, particularly in the hippocampus. These include increases in resting cerebral blood flow (CBF) and glutamatergic metabolite levels, and decreases in ligand binding to GABAA α5 receptors and to the synaptic density marker synaptic vesicle glycoprotein 2A (SV2A). However, direct links between inhibitory interneuron dysfunction and these neuroimaging readouts are yet to be established. Conditional deletion of a schizophrenia susceptibility gene, the tyrosine kinase receptor Erbb4, from cortical and hippocampal inhibitory interneurons leads to synaptic defects, and behavioral and cognitive phenotypes relevant to psychosis in mice.
STUDY DESIGN
Here, we investigated how this inhibitory interneuron disruption affects hippocampal in vivo neuroimaging readouts. Adult Erbb4 conditional mutant mice (Lhx6-Cre;Erbb4F/F, n = 12) and their wild-type littermates (Erbb4F/F, n = 12) were scanned in a 9.4T magnetic resonance scanner to quantify CBF and glutamatergic metabolite levels (glutamine, glutamate, GABA). Subsequently, we assessed GABAA receptors and SV2A density using quantitative autoradiography.
RESULTS
Erbb4 mutant mice showed significantly elevated ventral hippccampus CBF and glutamine levels, and decreased SV2A density across hippocampus sub-regions compared to wild-type littermates. No significant GABAA receptor density differences were identified.
CONCLUSIONS
These findings demonstrate that specific disruption of cortical inhibitory interneurons in mice recapitulate some of the key neuroimaging findings in patients with psychosis, and link inhibitory interneuron deficits to non-invasive measures of brain function and neurochemistry that can be used across species.
Identifiants
pubmed: 36573631
pii: 6961526
doi: 10.1093/schbul/sbac192
pmc: PMC10154722
doi:
Substances chimiques
Glutamine
0RH81L854J
Parvalbumins
0
Receptor, ErbB-4
EC 2.7.10.1
Erbb4 protein, mouse
EC 2.7.10.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-580Subventions
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202397/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT203148/Z/16/Z
Pays : United Kingdom
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Maryland Psychiatric Research Center.
Références
Neuroimage Clin. 2014 Jul 22;5:359-64
pubmed: 25161901
Mol Psychiatry. 2018 Aug;23(8):1764-1772
pubmed: 29311665
Mol Psychiatry. 2018 Nov;23(11):2227-2237
pubmed: 28727685
J Neurosci. 2009 Feb 25;29(8):2344-54
pubmed: 19244511
J Neurosci. 2007 Oct 24;27(43):11496-500
pubmed: 17959792
Schizophr Res. 2015 Sep;167(1-3):4-11
pubmed: 25449711
Nature. 2010 Apr 29;464(7293):1376-80
pubmed: 20393464
Mol Psychiatry. 2003 Sep;8(9):797-810
pubmed: 12931207
Eur Radiol. 2016 Dec;26(12):4404-4412
pubmed: 26943134
Mol Psychiatry. 2022 Jan;27(1):744-757
pubmed: 34584230
Mol Psychiatry. 2012 Jul;17(7):664-5
pubmed: 22212598
J Psychiatry Neurosci. 2021 Sep 1;46(5):E579-E582
pubmed: 34670841
Synapse. 1996 Apr;22(4):338-49
pubmed: 8867028
Brain Res Dev Brain Res. 1994 Sep 16;81(2):247-59
pubmed: 7813046
Neuropsychopharmacology. 2021 Jul;46(8):1468-1474
pubmed: 33941857
Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1211-6
pubmed: 20080551
Nature. 2014 Feb 13;506(7487):179-84
pubmed: 24463507
Am J Med Genet B Neuropsychiatr Genet. 2006 Mar 5;141B(2):142-8
pubmed: 16402353
Am J Med Genet B Neuropsychiatr Genet. 2013 Oct;162B(7):698-710
pubmed: 24132902
J Physiol. 2012 Feb 15;590(4):715-24
pubmed: 22219337
Commun Biol. 2022 Apr 19;5(1):372
pubmed: 35440709
Br J Pharmacol. 2011 Oct;164(4):1162-94
pubmed: 21449915
Br J Psychiatry. 2000 Mar;176:236-42
pubmed: 10755070
Neuron. 2010 Jan 14;65(1):7-19
pubmed: 20152109
Biol Psychiatry. 1998 Jul 15;44(2):88-97
pubmed: 9646890
Schizophr Res. 1999 Nov 9;40(1):23-9
pubmed: 10541003
Nat Rev Neurosci. 2012 Jan 18;13(2):107-20
pubmed: 22251963
Nat Rev Neurosci. 2010 Feb;11(2):100-13
pubmed: 20087360
NMR Biomed. 2001 Jun;14(4):260-4
pubmed: 11410943
Hippocampus. 2001;11(5):543-50
pubmed: 11732707
J Neurosci. 2020 Sep 30;40(40):7668-7687
pubmed: 32859716
Brain Res Mol Brain Res. 2005 Apr 27;135(1-2):104-11
pubmed: 15857673
J Womens Health (Larchmt). 2020 Jun;29(6):858-864
pubmed: 31971851
Cereb Cortex. 2003 Mar;13(3):252-64
pubmed: 12571115
Schizophr Bull. 2018 Oct 17;44(6):1323-1331
pubmed: 29294102
Schizophr Bull. 2019 Jan 1;45(1):148-157
pubmed: 29385549
Transl Psychiatry. 2017 Jun 6;7(6):e1147
pubmed: 28585933
Int J Neuropsychopharmacol. 2014 Oct;17(10):1609-19
pubmed: 24787547
Arch Gen Psychiatry. 2000 Jan;57(1):65-73
pubmed: 10632234
Nature. 2010 Nov 11;468(7321):232-43
pubmed: 21068832
Br J Pharmacol. 2019 Nov;176(21):4107-4118
pubmed: 30418665
Am J Psychiatry. 2015 Nov 1;172(11):1148-59
pubmed: 26133962
Nature. 2014 Feb 13;506(7487):185-90
pubmed: 24463508
Hippocampus. 2010 Jun;20(6):724-44
pubmed: 19655320
Philos Trans R Soc Lond B Biol Sci. 1999 Jul 29;354(1387):1165-77
pubmed: 10466144
J Nucl Med. 2016 May;57(5):777-84
pubmed: 26848175
Neuron. 2013 Sep 18;79(6):1152-68
pubmed: 24050403
Schizophr Res. 2012 Nov;141(2-3):262-5
pubmed: 23017826
Am J Psychiatry. 2019 Dec 1;176(12):1030-1038
pubmed: 31623459
Neurosurg Rev. 1991;14(3):163-8
pubmed: 1944930
J Magn Reson. 2010 Mar;203(1):66-72
pubmed: 20031459
Neuroimage. 2003 Oct;20(2):870-88
pubmed: 14568458
Neuroimage. 2014 Nov 15;102 Pt 2:838-47
pubmed: 25175535
Cereb Cortex. 2009 Jan;19(1):41-54
pubmed: 18440949
Am J Psychiatry. 2016 Apr 1;173(4):392-9
pubmed: 26684922
Neuropsychopharmacology. 2019 Jul;44(8):1349-1353
pubmed: 31048727
Neurosci Biobehav Rev. 2016 Aug;67:41-56
pubmed: 26743857
NPJ Schizophr. 2016 Jun 29;2:16022
pubmed: 27430010
J Neurol Neurosurg Psychiatry. 1998 Oct;65(4):446-53
pubmed: 9771764
JAMA Psychiatry. 2016 Jul 1;73(7):665-74
pubmed: 27304221
Schizophr Res. 2008 Feb;99(1-3):333-40
pubmed: 18042347
Am J Med Genet B Neuropsychiatr Genet. 2006 Jan 5;141B(1):96-101
pubmed: 16249994
Nature. 2016 Feb 11;530(7589):177-83
pubmed: 26814963
Annu Rev Physiol. 2003;65:401-27
pubmed: 12524459
Magn Reson Med. 1993 Dec;30(6):672-9
pubmed: 8139448
Proc Natl Acad Sci U S A. 2014 May 20;111(20):7450-5
pubmed: 24794528
Eur J Neurosci. 2013 Jan;37(1):80-95
pubmed: 23106361
Neuropsychopharmacology. 2022 Feb;47(3):687-695
pubmed: 34743200
Magn Reson Med. 2015 Jan;73(1):102-16
pubmed: 24715426
J Cereb Blood Flow Metab. 2012 Apr;32(4):731-44
pubmed: 22214903
Neurotox Res. 2010 Nov;18(3-4):367-76
pubmed: 20143199
Magn Reson Med. 2018 Mar;79(3):1314-1324
pubmed: 28585234
Front Neurosci. 2022 Mar 25;16:796129
pubmed: 35401097
Br J Psychiatry. 1992 Feb;160:179-86
pubmed: 1540757
Arch Gen Psychiatry. 2002 Jun;59(6):521-9
pubmed: 12044194
Behav Brain Res. 2004 Aug 12;153(1):159-70
pubmed: 15219717
Sci Transl Med. 2016 Jul 20;8(348):348ra96
pubmed: 27440727
Med Image Anal. 2008 Feb;12(1):26-41
pubmed: 17659998
Neuroimage. 2020 Jan 15;205:116278
pubmed: 31614221
Eur Neuropsychopharmacol. 2020 Dec;41:106-117
pubmed: 33153853
Mol Psychiatry. 2021 Jun;26(6):2616-2625
pubmed: 32296127
Mol Psychiatry. 2015 Apr;20(4):433-9
pubmed: 24912493
NMR Biomed. 2011 Dec;24(10):1235-42
pubmed: 21560175
Adv Pharmacol. 2006;54:231-63
pubmed: 17175817
Methods Mol Biol. 2018;1718:151-167
pubmed: 29341008
Mol Psychiatry. 2023 Apr 17;:
pubmed: 37069344
Dev Neurobiol. 2011 Jan 1;71(1):118-27
pubmed: 21154915
Nat Rev Neurosci. 2016 Aug;17(8):524-32
pubmed: 27256556
J Neurosci. 2007 Oct 10;27(41):10935-46
pubmed: 17928435
Magn Reson Med. 2017 Jan;77(1):23-33
pubmed: 26715192
J Cereb Blood Flow Metab. 2017 Jun;37(6):2137-2148
pubmed: 27466376
Schizophr Res. 2009 Oct;114(1-3):110-8
pubmed: 19683896
PLoS One. 2013 May 22;8(5):e63643
pubmed: 23717459
Psychiatry Res. 2015 Jun 30;232(3):219-25
pubmed: 25896442
Nat Commun. 2020 Jan 14;11(1):246
pubmed: 31937764
Hum Brain Mapp. 2018 Oct;39(10):4055-4064
pubmed: 29885018
Eur Neuropsychopharmacol. 2015 Dec;25(12):2210-20
pubmed: 26475576
Neuron. 2013 Apr 10;78(1):81-93
pubmed: 23583108
Mol Psychiatry. 2021 Dec;26(12):7690-7698
pubmed: 34135473
Neurosci Bull. 2020 Feb;36(2):97-109
pubmed: 31388929